News

Explore This Section

Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners

PALO ALTO, CA, USA, November 14, 2023 – Autobahn Labs, an early-stage drug discovery incubator, announced today that it had executed exclusive license agreements to foundational technologies in its collaborations with the Los Angeles and San Francisco campuses of the University of California. The objective of Autobahn’s collaborations with its academic partners is to identify academic research programs targeting important unmet medical needs and to advance their commercialization in companies it launches.

Inspiring Women in Science: Yvonne Chen

To help get more girls interested in STEM, let’s spotlight inspiring women in science! A great example is Yvonne Chen, who is doing life-saving research. She is co-founder of ImmPACT Bio, which is based in Camarillo, California. The biotech company recently received positive results in its Phase 1 clinical study in relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (R/R B-cell NHL).

Read the Entire Article Here

TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

Dennis Slamon UCLA Researcher

Congratulations to Dennis Slamon, M.D., Ph.D., Professor of Medicine, and Chief of the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine (DGSOM) (pictured above) co-founder of TORL BioTherapeutics LLC on a successful launch!